

2009-014407-31

Randomized phase II trial with Irinotecan, Cetuximab and Everolimus (ICE) compared to Capecitabine and Oxaliplatin (CapOx) for patients with Gemcitabine-resistant pancreatic cancer.

Sponsor: Odense University Hospital

Principal Investigator: Per Pfeiffer

The trial ended prematurely on Dec. 15th 2012 due to slow recruitment and a further decrease in recruitment due to new data published during the trial.

The protocol was established in 2 of 3 planned centres. This was delayed due to several logistical reasons. This resulted in a satisfactory recruitment for the phase I part, but un-satisfactory in the phase II part.

Results of a phase III study were published during the trial. This demonstrated superiority of a combination of Oxaliplatin, Irinotecan and 5-FU in the first line setting. As the protocol could not include patients treated with Oxaliplatin or Irinotecan, the recruitment rate declined further, without expectations of improvement.